From EADV: Rezpegaldesleukin Effective Through 24 Weeks in REZOLVE-AD Trial
Key Takeaways
New data presented at EADV 2025 showed rezpegaldesleukin meeting primary and key secondary endpoints at week 16 in moderate-to-severe AD patients.
Extended dosing to 24 weeks led to improved EASI-75 and vIGA-AD 0/1 response rates in crossover patients.
New data from the REZOLVE-AD presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress demonstrated that investigational IL-2 pathway agonist rezpegaldesleukin sustained effect beyond the 16-week induction period in patients with moderate-to-severe atopic dermatitis (AD).
Researchers for the late-breaking oral abstract reported that it had met its primary endpoint (mean improvement in EASI score from basline), with statistically significant improvements in mean EASI scores at week 16 across all dosing arms compared to placebo. There were also benefits reported for key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD 0/1, and BSA.
In patients on placebo during induction and who crossed over to 24 weeks of high-dose rezpegaldesleukin (24 µg/kg q2w), interim data showed sustained clinical improvement: EASI-75 rates deepened from 50% at crossover week 16 to 62% at week 24, and vIGA-AD 0/1 rates increased from 28% to 38%.
"These data from REZOLVE-AD presented today show a rapid onset of treatment effect for both clinician-assessed and patient-reported outcomes following the first few doses of rezpegaldesleukin," Prof. Jonathan Silverberg, MD, PhD, MPH, in a press release. "In addition, for the first time, we observe a deepening of clinical effect for patients with extended dosing of investigational therapy beyond 16 weeks, with a strengthening of absolute EASI reduction, along with higher EASI-75 and vIGA 0/1 response rates following 24 weeks of treatment. These results build on the body of data generated to-date for rezpegaldesleukin that show the advantage of this novel, broad-based Treg mechanism over other novel mechanisms in development to treat atopic dermatitis."
Source: Nektar Therapeutics press release, September 18, 2025.